A PYMNTS Company

AbbVie, Abbott Sued by Perrigo Over AndroGel Generic Delay

By  |  May 4, 2020

Perrigo sued AbbVie in Philadelphia federal court Monday, claiming its scheme to delay competition for the blockbuster testosterone booster AndroGel kept the Israeli drugmaker’s generic version off pharmacy shelves, reported Bloomberg Law. 

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The antitrust lawsuit also targets AbbVie’s former parent Abbott Laboratories, AbbVie subsidiary Unimed Pharmaceuticals, and Besins Healthcare, a Belgian company that partnered with Unimed to develop AndroGel. It was filed in the US District Court for the Eastern District of Pennsylvania.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.